Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 3rd
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago.
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
Here's Why Agios Stock Plummeted More Than 20% on Monday
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
4 Medical Product Stocks to Buy From a Prospective Industry
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.
